Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

PEPTIDE DRUGS AGAINST INFLUENZA VIRUS

Award Number: R41AI068230
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2006
PERIOD OF PERFORMANCE END DATE: 07/31/2008

Group Awards By:

View Award Description

PEPTIDE DRUGS AGAINST INFLUENZA VIRUS - DESCRIPTION (provided by applicant): Influenza virus is 1 of the most important human pathogens accounting for widespread morbidity and mortality. Influenza virus is currently classified as a NIAID Biodefense Category C priority pathogen, a status that may be upgraded due to the recent emergence of a highly virulent strain of avian influenza virus in Thailand, Vietnam, North Korea and other Asian countries. On average, more than 35,000 people per year die from influenza virus infection in the United States. Highly virulent strains of influenza virus can rapidly achieve pandemic status in which millions or even tens of millions of people can die. The potential for human pathogenic strains to arise, via crossover from birds or other species, then reassortment, is well established. Both the World Health Organization and the Centers for Disease Control and Prevention have declared that it is only a matter of time before the next worldwide flu pandemic. The new strains of bird flu appear to be resistant to amantadine and related influenza drugs. Hemagglutinin, the membrane fusogenic envelope glycoprotein of influenza viruses, shares several common structural features with the fusion proteins of an otherwise diverse group of enveloped RNA viruses. These conserved structural domains are important in influenza virus infection, entry and pathogenesis. The studies proposed will determine whether synthetic peptides corresponding to motifs of the influenza virus glycoproteins can interfere with fusion/infectivity by influenza viruses. The premise of this STTR application is that because of salient similarities between the fusion proteins of influenza virus and other RNA viruses that a body of prior research can be used to guide studies of drug development against this serious public health threat and potential bioterrorism agent. Specific Aim 1 is to identify peptides corresponding to sequences in influenza virus glycoproteins that inhibit virus infectivity. Molecular modeling and algorithms, including the Wimley-White interfacial hydrophobicity scale, will be used to identify candidate peptides. Specific Aim 2 is to evaluate the efficacy of lead peptides in ferrets, the small animal model that best recapitulates human influenza virus pathogenesis. Specific Aim 3 is to elucidate the steps in the virus replication cycle at which active peptides inhibit influenza virus infection. Specific Aim 4 is to optimize peptides showing antiviral activity in ferrets for inhibition of influenza virus infectivity by modifications that increase stability, solubility, and target the peptides to intracellular compartments. The studies proposed in this application will address an urgent public health and biodefense need for new drugs that are effective against influenza viruses.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2007 ( Subtotal = $461,944 )
2007	2007	AUTOIMMUNE TECHNOLOGIES, LLC	144 ELKS PLACE SUITE 1402	NEW ORLEANS	LA	70112	ORLEANS	USA	Microbiology and Infectious Diseases Research	000	2	7/23/2007	NON-COMPETING CONTINUATION	$461,944
														Subtotal = $461,944

Issue Date FY: 2006 ( Subtotal = $460,957 )
2006	2006	AUTOIMMUNE TECHNOLOGIES, LLC	144 ELKS PLACE SUITE 1402	NEW ORLEANS	LA	70112	ORLEANS	USA	Microbiology and Infectious Diseases Research	000	1	7/19/2006	NEW	$460,957
														Subtotal = $460,957

Grand Total All Awards = $922,901

Top

All Categories

About

Search

Reports

Data Submission

Award Information

PEPTIDE DRUGS AGAINST INFLUENZA VIRUS

Award Number: R41AI068230

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2006

PERIOD OF PERFORMANCE END DATE: 07/31/2008

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer